Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00747058 | A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects | PHASE1 | COMPLETED | 28 | — | — | Aug 1, 2008 | Dec 1, 2008 | Jan 8, 2010 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| healthy volunteers | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-3864086 | DRUG | The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well. |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * healthy male volunteers * no drug history * no other medication for 28 pre-dose Exclusion Criteria: * age below 21 years * age above 55 years